CCCC vs. RCKT, ZYME, ADPT, GYRE, PSTX, OCS, NUVB, AVXL, ABCL, and CVAC
Should you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Rocket Pharmaceuticals (RCKT), Zymeworks (ZYME), Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Oculis (OCS), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.
C4 Therapeutics vs.
C4 Therapeutics (NASDAQ:CCCC) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
In the previous week, C4 Therapeutics had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for C4 Therapeutics and 3 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.23 beat C4 Therapeutics' score of 0.03 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.
Rocket Pharmaceuticals has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Rocket Pharmaceuticals' return on equity.
C4 Therapeutics presently has a consensus price target of $10.67, indicating a potential upside of 170.73%. Rocket Pharmaceuticals has a consensus price target of $47.27, indicating a potential upside of 358.51%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than C4 Therapeutics.
78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 8.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 28.5% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
C4 Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
C4 Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
Rocket Pharmaceuticals received 364 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 73.22% of users gave Rocket Pharmaceuticals an outperform vote while only 39.13% of users gave C4 Therapeutics an outperform vote.
Summary
Rocket Pharmaceuticals beats C4 Therapeutics on 9 of the 17 factors compared between the two stocks.
Get C4 Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
C4 Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CCCC) was last updated on 1/20/2025 by MarketBeat.com Staff
Free CCCC Stock Alerts